Mersana Therapeutics, Inc.
MRSN
$7.65
-$0.10-1.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.06M | 2.75M | 16.36M | 12.60M | 2.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.06M | 2.75M | 16.36M | 12.60M | 2.29M |
| Cost of Revenue | 16.22M | 18.34M | 22.29M | 14.80M | 17.25M |
| Gross Profit | -13.16M | -15.59M | -5.93M | -2.21M | -14.95M |
| SG&A Expenses | 7.42M | 8.93M | 8.89M | 9.86M | 10.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.63M | 27.27M | 31.17M | 24.67M | 27.75M |
| Operating Income | -20.58M | -24.51M | -14.81M | -12.07M | -25.46M |
| Income Before Tax | -24.30M | -24.12M | -14.12M | -11.08M | -24.27M |
| Income Tax Expenses | -- | -- | 0.00 | 418.00K | -- |
| Earnings from Continuing Operations | -24.30M | -24.12M | -14.12M | -11.50M | -24.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.30M | -24.12M | -14.12M | -11.50M | -24.27M |
| EBIT | -20.58M | -24.51M | -14.81M | -12.07M | -25.46M |
| EBITDA | -20.29M | -24.20M | -14.41M | -11.67M | -25.05M |
| EPS Basic | -4.87 | -4.85 | -2.86 | -2.34 | -4.96 |
| Normalized Basic EPS | -2.55 | -3.03 | -1.79 | -1.41 | -3.10 |
| EPS Diluted | -4.87 | -4.85 | -2.86 | -2.34 | -4.96 |
| Normalized Diluted EPS | -2.55 | -3.03 | -1.79 | -1.41 | -3.10 |
| Average Basic Shares Outstanding | 4.99M | 4.98M | 4.94M | 4.91M | 4.90M |
| Average Diluted Shares Outstanding | 4.99M | 4.98M | 4.94M | 4.91M | 4.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |